Companies › Shanton Pharma Pte.
1 active drug program in 47 registered trials: 22 Phase 3, 13 Phase 2, 10 Phase 4, 2 Phase 1; Neurology, Cardiovascular, Genitourinary, Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Colchicine (SAP-001) Tubulin inhibitor | Tubulin | Phase 2 | Gout; Colchicine; Persistent Atrial Fibrillation; Coronary Artery Disease … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05690204 | Colchicine (SAP-001) | Phase 2 | Gout | Metabolic and endocrine | Jan 2025 |
| NCT06729853 | Colchicine (SAP-001) | Phase 1 | Gout | Metabolic and endocrine | Jan 2025 |
| NCT06837623 | Colchicine (SAP-001) | Phase 3 | HFpEF - Heart Failure With Preserved Ejection Fraction | Cardiovascular | Feb 2025 |
| NCT04916522 | Colchicine (SAP-001) | Phase 2 | Hypertension | Cardiovascular | Jan 2026 |
| NCT05472337 | Colchicine (SAP-001) | Phase 2 | Acute Coronary Syndrome | Cardiovascular | Mar 2026 |
| NCT05162742 | Colchicine (SAP-001) | Phase 3 | Aortic Valve Disease | Cardiovascular | Dec 2026 |
| NCT07247734 | Colchicine (SAP-001) | Phase 2 | Type 1 Diabetes | Immunology | Dec 2026 |
| NCT07287345 | Colchicine (SAP-001) | Phase 4 | Colchicine | Cardiovascular | Dec 2026 |
| NCT06118034 | Colchicine (SAP-001) | Phase 3 | Inflammatory Response | Cardiovascular | Dec 2026 |
| NCT05890664 | Colchicine (SAP-001) | Phase 3 | Atrial Fibrillation | Cardiovascular | Mar 2027 |
| NCT06765356 | Colchicine (SAP-001) | Phase 4 | Persistent Atrial Fibrillation | Cardiovascular | Mar 2027 |
| NCT05850091 | Colchicine (SAP-001) | Phase 4 | Coronary Artery Disease | Cardiovascular | Jun 2027 |
| NCT05335148 | Colchicine (SAP-001) | Phase 1 | Radiation Therapy | Immunology | Jun 2027 |
| NCT05873881 | Colchicine (SAP-001) | Phase 3 | Heart Failure | Cardiovascular | Jun 2027 |
| NCT06472908 | Colchicine (SAP-001) | Phase 3 | Coronary Heart Disease | Cardiovascular | Jun 2027 |
| NCT06472908 | Colchicine (SAP-001) | Phase 3 | Coronary Heart Disease | Cardiovascular | Jun 2027 |
| NCT07571681 | Colchicine (SAP-001) | Phase 2 | Hashimoto Thyroiditis | Immunology | Jul 2027 |
| NCT07837934 | Colchicine (SAP-001) | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | Cardiovascular | Jul 2027 |
| NCT05476991 | Colchicine (SAP-001) | Phase 3 | Stroke | Cardiovascular | Sep 2027 |
| NCT05503225 | Colchicine (SAP-001) | Phase 2 | ICAD - Intracranial Atherosclerotic Disease | Cardiovascular | Sep 2027 |
| NCT06802926 | Colchicine (SAP-001) | Phase 4 | CABG | Other | Oct 2027 |
| NCT06090890 | Colchicine (SAP-001) | Phase 4 | In-stent Restenosis | Other | Oct 2027 |
| NCT06095765 | Colchicine (SAP-001) | Phase 3 | Coronary Artery Disease | Cardiovascular | Nov 2027 |
| NCT07362966 | Colchicine (SAP-001) | Phase 4 | Colchicine | Cardiovascular | Dec 2027 |
| NCT06440694 | Colchicine (SAP-001) | Phase 3 | Venous Thromboembolism | Cardiovascular | Dec 2027 |
| NCT05633810 | Colchicine (SAP-001) | Phase 3 | Diabete Type 2 | Cardiovascular | Dec 2027 |
| NCT07026994 | Colchicine (SAP-001) | Phase 2 | Cerebral Amyloid Angiopathy | Neurology | Dec 2027 |
| NCT06130059 | Colchicine (SAP-001) | Phase 2 | Heart Failure | Cardiovascular | Dec 2027 |
| NCT06763055 | Colchicine (SAP-001) | Phase 3 | Intracerebral Hemorrhage | Neurology | Jan 2028 |
| NCT05855746 | Colchicine (SAP-001) | Phase 3 | Acute Myocarditis | Immunology | Jan 2028 |
| NCT06813079 | Colchicine (SAP-001) | Phase 2 | Pancreatic Ductal Carcinoma | Oncology | Feb 2028 |
| NCT06279000 | Colchicine (SAP-001) | Phase 3 | Cardiovascular Diseases | Cardiovascular | Mar 2028 |
| NCT06158698 | Colchicine (SAP-001) | Phase 3 | Cardiomyopathies | Cardiovascular | May 2028 |
| NCT06286423 | Colchicine (SAP-001) | Phase 4 | Heart Failure | Cardiovascular | Jun 2028 |
| NCT05618353 | Colchicine (SAP-001) | Phase 4 | Coronary Artery Disease | Cardiovascular | Jul 2028 |
| NCT05928728 | Colchicine (SAP-001) | Phase 3 | Atrial Fibrillation | Cardiovascular | Nov 2028 |
| NCT06543082 | Colchicine (SAP-001) | Phase 4 | Acute Coronary Syndrome | Cardiovascular | Dec 2028 |
| NCT07704164 | Colchicine (SAP-001) | Phase 2 | HIV Infection | Infectious disease | Dec 2028 |
| NCT06998862 | Colchicine (SAP-001) | Phase 3 | Chronic Kidney Disease | Genitourinary | Dec 2028 |
| NCT02939573 | Colchicine (SAP-001) | Phase 2 | Primary Cutaneous Vasculitis | Immunology | Dec 2028 |
| NCT06578182 | Colchicine (SAP-001) | Phase 3 | Osteoarthritis, Knee | Immunology | Mar 2029 |
| NCT07536373 | Colchicine (SAP-001) | Phase 3 | Chronic Limb-Threatening Ischemia | Cardiovascular | Apr 2029 |
| NCT04774159 | Colchicine (SAP-001) | Phase 3 | Peripheral Arterial Disease | Cardiovascular | Dec 2029 |
| NCT07349875 | Colchicine (SAP-001) | Phase 4 | Coronary Artery Disease (CAD) | Cardiovascular | Dec 2029 |
| NCT05949281 | Colchicine (SAP-001) | Phase 2 | Type 1 Diabetes | Cardiovascular | Jan 2031 |
| NCT06930885 | Colchicine (SAP-001) | Phase 3 | Atherothrombotic Diseases | Cardiovascular | May 2031 |
| NCT07232069 | Colchicine (SAP-001) | Phase 3 | Coronary Artery Disease Risk Factors Multiple | Cardiovascular | Jul 2031 |
Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen Fidia Farmaceutici GSK Beijing Biostar Pharmaceuticals Urotronic
Gradalis Beijing Biostar Pharmaceuticals Merz Therapeutics ArthroBiologix CellTrans
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.